Lucence
PrivateLast Round
Series A
Extension
Nov 10, 2023
Total Funding Raised
$74.35M
Company Overview
Lucence operates in Healthcare & Life Sciences and is based in Palo Alto, California. Its latest recorded funding round was a Series A Extension round in November 2023.
Lucence is a precision oncology company that develops non-invasive liquid biopsy tests for early cancer detection and treatment selection.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lucence Comparables
Compare Lucence with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Predicine | 83% | |
| Circulogene | 83% | |
| Guardant Health | 80% |
For institutional investors. Book with your work email.
Lucence Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 10, 2023 | ||||
| Series A | Nov 20, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Lucence Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chen Capital Ventures | Series A Extension |
| Heliconia Capital | Series A, Series A Extension |
| SGInnovate | Series A |
| Openspace Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2025
Grew 18% QoQ, from 83 to 98 employees.
- Jul 1, 2025
Monthly visitors increased 88% MoM, reaching 3,000.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 3, 2026
Lucence Health Inc. works with Qiagen Sa on SG-INSIGHT in Singapore, combining sample preparation technologies with sequencing and bioinformatics capabilities for Phase III of Singapore’s National Precision Medicine program.
- launchesSep 22, 2026
Lucence Health Inc. plans to launch a urine-based test for kidney, bladder and prostate cancer by end of 2026, with lower costs expected.
For institutional investors. Book with your work email.
Lucence Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Lucence's valuation, stock price, and market status.
Is Lucence a public or private company?
Lucence is a private company.
What is the current stock price of Lucence?
Lucence is a private company, so its shares have no public market price. Caplight tracks Lucence's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lucence worth (valuation)?
Valuation information for Lucence is not publicly available.
Can I buy Lucence stock?
Lucence shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lucence's last funding round?
Lucence's most recent funding round was Series A Extension on November 10, 2023.
Who are the main investors in Lucence?
Key investors in Lucence include Chen Capital Ventures, Heliconia Capital, Openspace Capital.
Will Lucence IPO soon?
No public IPO plans have been announced for Lucence.
How can I track Lucence secondary market activity?
Caplight tracks bids, offers, and trades in Lucence's shares on secondary markets.